SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell antitumor immunity and synergize with anti-PD-1, highlighting SSRIs as potential cancer immunotherapeutics. Here, SLC6A4 is linked to cancer.